# Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

> **NCT05536973** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Adverum Biotechnologies, Inc.** · enrollment: 69 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **GENETIC:** ADVM-022
- **GENETIC:** ADVM-022

## Key facts

- **NCT ID:** NCT05536973
- **Lead sponsor:** Adverum Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-23
- **Primary completion:** 2024-08-26
- **Final completion:** 2028-08
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05536973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05536973, "Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05536973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*